Microbial biofilms are communities of cells that adhere to solid surfaces or are present at liquid-air interfaces, and they are considered the most common state of growth for many microbial species [1] [2] [3] . Cells within biofilms have properties that are distinct from their planktonic (free-floating) counterparts; for example, they are often more resistant to drugs and to physical perturbations 4 . Microbial biofilms have been observed in aquatic environments, on artificial industrial structures, on implanted medical devices, and on plant and mammalian tissues 1 . Although many microorganisms are capable of forming single-species biofilms, it is much more common to find two or more bacterial and/or fungal species in a biofilm; these polymicrobial biofilms often provide specific advantages to each species when compared with single-species biofilms 5 . In several programme announcements for funding (PA-03-047 and PA-07-288), the National Institutes of Health (NIH) estimates that biofilms are responsible for a ~80% of microbial infections in humans 1, 6 . Candida species are the predominant fungi isolated from infected medical devices and account for ~15% of hospital-acquired cases of sepsis 1 . Candida albicans is the most commonly identified Candida species in clinical contexts and is one of the leading causes of hospital-acquired infections. However, in healthy humans, C. albicans is usually a harmless member of the native microbiota and asymptomatically colonizes many niches, including the gastrointestinal tract, reproductive tract, mouth and skin [7] [8] [9] [10] [11] . Disturbances caused by shifts in pH, nutritional alterations, shifts in oxygen levels, antibiotic use, diseases, or immunosuppressant therapy can promote the over-proliferation of C. albicans and often lead to severe symptoms. C. albicans infections range from superficial mucosal and dermal infections to disseminated bloodstream infections with mortality rates above 40% [12] [13] [14] . C. albicans infections are particularly serious in immunocompromised individuals, such as patients with AIDS, patients undergoing chemotherapy and individuals receiving immunosuppressant therapies. In addition, individuals who have implanted medical devices are also particularly susceptible 15, 16 . C. albicans biofilms are highly structured; they contain yeast-form cells, pseudohyphal cells and hyphal cells surrounded by an extracellular matrix 6,17,18 (FIG. 1) . In addition to forming biofilms on implanted medical devices (for example, catheters, pacemakers, heart valves, joint prostheses and dentures), C. albicans biofilms also form on host surfaces, including mucosal surfaces, epithelial cell linings and parenchymal organs 19, 20 . Existing anti fungal drugs, at concentrations effective against planktonic C. albicans, are largely ineffective against C. albicans cells in biofilms. Although much higher concentrations can be effective against biofilms, these doses often cause serious side effects to the host (that is, kidney or liver damage). Resistance to antifungal drugs associated with C. albicans biofilms and the ability to colonize implanted medical devices have been linked to increased medical costs and negative patient outcomes [19] [20] [21] [22] [23] [24] . C. albicans biofilms function as reservoirs of drug-resistant cells that can detach, multiply and seed bloodstream infections. If a recalcitrant biofilm infection is suspected, removal of the infected 
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Persister cells
Non-dividing fungal cells with decreased metabolic activity that are resistant to antimicrobial agents.
device is typically the standard procedure 25, 26 ; however, depending on the device, the removal can require invasive and potentially dangerous surgical procedures (for example, the treatment of heart valves is especially problematic). Critically ill patients are often unable to tolerate these procedures, leaving few, if any, available treatment options in these cases 19, 26 . In this Review, we provide an overview of the processes involved in the formation of a C. albicans biofilm and discuss the transcriptional circuitry that regulates biofilm development. We also consider some of the advantages that biofilms provide to C. albicans compared with planktonic growth and explore polymicrobial biofilms that are formed by C. albicans and certain bacterial species. Finally, we discuss several recent advances in the field, including the identification of new regulators of biofilm formation, the identification and characterization of biofilm-specific proteolysis, the proteomic characterization of persister cells, the analyses of naturally occurring C. albicans strains with differing abilities to form biofilms and the protection that biofilms confer against the host immune system.
C. albicans biofilm formation
The current understanding of C. albicans biofilm development is based on in vitro experiments, in vivo animal models of infection, and examination of biofilms that formed on medical devices in the clinic
. On the basis of those observations, C. albicans biofilm development has been divided into four stages: adherence, initiation (also referred to as proliferation), maturation and dispersion 17, [27] [28] [29] [30] [31] (FIG. 1) . In vitro results suggest that biofilm formation begins with the adherence of yeast-form cells to a solid surface and the formation of a basal layer that functions to anchor the biofilm. C. albicans cells adhere to both biotic and abiotic surfaces with consistencies ranging from hard to soft. This feature, coupled with the ability to adhere to other C. albicans cells, contributes to 
White-opaque switching
The ability for Candida albicans cells to switch between the 'white' and 'opaque' phenotypic cell types. The switch occurs epigenetically; that is, without a change in the primary DNA sequence of the genome.
Horizontal gene transfer
The process through which genetic material is transferred between microorganisms through mechanisms such as transformation, conjugation and transduction. This process is distinct from vertical gene transfer, in which genetic material is transferred from mother cells to daughter cells.
Quorum sensing
A method of communication that allows microorganisms to sense cell density and microbial community composition and respond as a group. The process involves the production and detection of soluble quorum sensing molecules.
the structural integrity of biofilms and is the crucial first step in biofilm formation. Following adherence, these cells proliferate as yeast-form cells and remain attached to the anchor layer. Subsequently, pseudohyphal and hyphal cells begin to form from these dividing yeast-form cells, and they continue to elongate and proliferate throughout the completion of biofilm formation. Under most in vitro experimental conditions, the biofilm is considered mature by ~24 h and is characterized by a structured mixture of yeast-form, pseudohyphal and hyphal cells that are surrounded by an extracellular matrix that is composed of proteins, carbohydrates, lipids and nucleic acids. The biofilm matrix functions as a protective physical barrier from the environment and provides structural integrity to the biofilm, and it is critical in the resistance of mature biofilms to mechanical disruption. The presence of the matrix is most pronounced during and after the maturation stage of biofilm development. At those stages, the biofilm has a thick (several hundred micrometres), structured appearance with distinct layers (yeast-form cells towards the solid surface, hyphal and pseudohyphal cells extending away from the surface, and the extracellular matrix encompassing all cells). The hyphae that form in the later stages of C. albicans biofilm development form a scaffold that supports the different components of the biofilm, thereby contributing to the overall architectural stability of the biofilm structure. Once fully matured, the biofilm slowly disperses predominantly yeast-form cells that bud off from hyphae, thus contributing to the dissemination of the infection 1, 32 . Although the general progression of biofilm development and the properties of the mature structure have been studied primarily in vitro, many of the same features (for example, a several-hundredmicrometre-thick biofilm consisting of yeast-form cells at the base, hyphal and pseudohyphal cells throughout the structure, and a thick extracellular matrix) have also been observed in vivo in rabbit, mouse and rat catheter models, in vivo in rat denture models, and in vivo and ex vivo in mouse vaginal models. C. albicans biofilms have also been extensively observed in clinical settings, for example on catheters and dentures of patients [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] .
Regulation of biofilm development
In light of the large number of differences between biofilm cells and planktonic cells, it is not surprising that more than 50 transcriptional regulators have been linked to the formation of C. albicans biofilms 1, [43] [44] [45] ( FIG. 2; TABLE 1 ). Cells in which those genes have been deleted exhibit a range of phenotypes with regard to biofilms, including moderately reduced thickness of the mature biofilm (for example, an ndt80 deletion mutant), extremely thin biofilms (for example, an efg1 deletion mutant), abnormally thick biofilms (for example, an rfx2 deletion mutant), lack of hyphal cells within the biofilm structure (for example, a bcr1 deletion mutant) and reduced adherence to the solid substrate (for example, an rfg1 deletion mutant) 46, 47 . Genetic screens that were carried out with collections of C. albicans deletion mutants identified a 'core' set of nine regulators (Bcr1, Brg1, Efg1, Flo8, Gal4, Ndt80, Rob1, Rfx2 and Tec1) that is required for biofilm development both in vitro on polystyrene plates and on silicone squares, and in vivo in the rat catheter and denture models [46] [47] [48] . Chromatin immunoprecipitation experiments revealed that these nine regulators form a highly interconnected transcriptional network (FIG. 2) in which the individual regulators control each other and, in addition, ~1,000 target genes 46, 47 . The complex, highly interconnected structure of this network is similar to those of regulatory networks controlling complex processes such as white-opaque switching in C. albicans 49 , pseudohyphal growth in Saccharomyces cerevisiae 50 and even development of mouse pluripotent embryonic stem cells 51 . Some of the target genes in the biofilm network themselves encode transcriptional regulators, several of which were subsequently shown to also be required for biofilm formation (for example, Grf10 and Sfp1) (TABLE 1). Other regulatory targets are required for specific processes in biofilm formation, such as hyphal growth (for example, Hwp1), the production of the extracellular matrix (for example, Gsc1 and Mnn1) and drug resistance (for example, Cdr1 and Mdr1). However, the functions of most target genes remain to be determined, as most of them lack clear homology with characterized genes from other organisms 46 . Consistent with this observation, orthology mapping suggests that the targets of the C. albicans biofilm network are enriched for genes that evolved more recently, after the Candida clade diverged from a non-pathogenic ancestor 46 . Thus, many of the target genes in the biofilm network are 'novel' genes (that is, genes that have rapidly evolved or were acquired by horizontal gene transfer) and their functions remain to be determined. In the following sections, we discuss recent updates to this regulatory circuit that are crucial for the individual steps of C. albicans biofilm formation.
Adherence. Although we lack detailed understanding of how C. albicans cells adhere to surfaces, current evidence indicates that the nature of the surface, molecules involved in quorum sensing, host hormones and the presence of other interacting microorganisms can influence this initial step of biofilm formation [52] [53] [54] [55] [56] [57] [58] [59] . The specific genes involved in adherence, both in the early stages of 151 . Whereas biofilms can be directly observed using some in vitro assays (for example, confocal laser-scanning microscopy and biofilm formation on silicone squares) 46, 48 , other methods rely on correlated readouts for biofilm formation (for example, dry weight and optical density) 46, 61, 68, 152 . Measurements of cell viability (for example, metabolic reduction of the tetrazolium salt reagent XTT) 153, 154 and dye uptake (for example, crystal violet incorporation into the biofilm) 155 are also commonly used as readouts to evaluate biofilm formation in vitro.
Regarding in vivo assays, rabbit, mouse and rat catheter models, avascular subcutaneous catheter models, rat denture models and mouse vaginal models have all been used to study biofilm formation in a host [33] [34] [35] 38, 39, 42, 156, 157 . In the future, we can anticipate the results from additional model systems currently in development, such as those involving live imaging of animals and optical scanners 149, 150, 158 .
Glycosylphosphatidylinositol (GPI) anchors
Post-translational modifications of proteins in which a glycolipid is covalently attached and anchors the protein in the plasma membrane.
Flow cell
A light microscopy method for observing biofilm formation in vitro under laminar flow conditions.
Glucoamylase
An enzyme that catalyses the hydrolysis of glucosidic linkages in starch, which releases glucose.
Glucan synthase
A glucosyltransferase enzyme that catalyses the synthesis of glucans, which are critical polysaccharide components of the fungal cell wall and the extracellular matrix.
biofilm formation and in the later maturation phases, thus have important roles in biofilm formation and maintenance. For example, a group of ten genes (including ALS1, ALS2, ALS4 and PGA6) is upregulated early in biofilm formation, whereas a different set of ten genes (including IFF4, IFF6, PGA32 and PGA55) is upregulated at later time points 47 . Most of these genes encode proteins that exhibit homology to documented fungal adhesins 52, 60 and contain glycosylphosphatidylinositol (GPI) anchors; they were designated 'adhesion genes' based on experiments that established their requirement for adhesion of C. albicans in at least one assay measuring cellular adherence (of note, not necessarily in assays of biofilm formation). Of the ten 'early' adhesion genes, five (ALS1, ALS2, ALS3, EAP1 and MSB2) have been shown to be directly required for biofilm formation based on genetic studies in which they have been deleted 46, [61] [62] [63] [64] [65] . Considerably less is known about the 'late' adhesion genes, as most have not been directly tested for either adhesion or biofilm formation 46, 66 . Several models have been proposed to explain the chemical basis for adhesion-mediated adherence to biotic and abiotic surfaces and were recently reviewed 67 . However, the process of adherence involves many more genes than those encoding adhesins. Using a silicone surface in an in vitro flow cell, more than 30 transcriptional regulators were shown to be required for adherence 64 . At least four of these regulators (Bcr1, Ace2, Snf5 and Arg81) are also required for adherence to polystyrene, and one of them (Bcr1) is required for biofilm formation under all conditions reported 46, 48, 64 . The role of Bcr1 is not surprising given its regulatory role in the expression of several cell wall proteins necessary for adherence (for example, Als1, Als3 and Hwp1) 48, 61, 68, 69 . It may seem counterintuitive that so many other transcriptional regulators are also required for the initial adherence step in biofilm formation; however, this observation indicates how little we currently understand about this step in biofilm formation.
Production of the extracellular matrix. A mature C. albicans biofilm is encased in an extracellular matrix that is a mixture of glycoproteins (55%), carbohydrates (25%; largely α-mannan and β-1,6-glucan polysaccharides, and, to a lesser extent, β-1,3-glucan), lipids (15%) and nucleic acids (5%) 70 . More than 500 proteins have been identified by mass spectrometry in the matrix, and many of them are enzymes 70 . It has been noted that many of the enzymes found in the matrix lack canonical secretion sequences and are thus unlikely to be secreted enzymes, which suggests that the matrix contains a small fraction of lysed cells in addition to other components 70 .
Although not yet experimentally validated, these extracellular enzymes could have several functions, including the digestion of cellular components to provide nutrients for C. albicans, promotion of cell dispersion and the protection of fungal cells from destruction by host immune cells 70 . Very little is known about the presence of extracellular DNA (eDNA) in the C. albicans biofilm matrix, but similar to bacterial biofilms, there is evidence that eDNA contributes to the stability of C. albicans biofilms. In agreement with this notion, one study has shown that eDNA is present at all stages of biofilm development and that treatment with DNase decreases biofilm biomass at later time points in biofilm formation 71 . Two transcriptional regulators, Rlm1 and Zap1 (also known as Csr1), have been implicated in matrix production. Deletion of ZAP1 was shown to increase matrix formation, potentially through the upregulation of Gca1 and Gca2 (REF. 72 ), which are glucoamylase enzymes that convert long-chain polysaccharides into smaller-chain polysaccharides. Deletion of RLM1 reduces matrix formation, potentially through downregulation of the Gsc1 (also known as Fks1) β-1,3-glucan synthase subunit 73 , which catalyses the formation of β-1,3-glucan. Mutations in genes encoding enzymes that produce polysaccharide components of the matrix (ALG11, MNN4-4, MNN9, MNN1, PMR1, VAN1 and VRG4 involved in mannan synthesis, BIG1 and KRE5 involved in β-1,6-glucan synthesis, and GSC1 involved in β-1,3-glucan synthesis) result in broad defects in matrix synthesis 74 , which highlights their crucial role in the production of the matrix and biofilm development.
Formation of hyphal cells. C. albicans can form hyphal cells both in planktonic cultures and during the maturation step of biofilm formation 1, 32, 75 . Many of the same gene products, including transcriptional regulators and structural proteins, are important for hyphal formation in Nature Reviews | Microbiology 
Chromatin-modifying complex
A protein complex that alters the chromatin structure.
both of these contexts. For example, several of the previously mentioned core regulators of biofilm formation (for example, Efg1, Ndt80, Rob1 and Tec1) are also involved in the regulation of hyphal growth in planktonic cells; deletion of any one of these genes reduces or even eliminates the formation of hyphae under planktonic conditions 46, 76, 77 . Further support for the link between hyphal growth in planktonic cells and biofilms comes from a screen of kinase deletion mutants; those with defects in hyphal formation in suspension cultures were also defective in biofilm formation 78 . Furthermore, transcriptional profiling studies of C. albicans clinical isolates with varying abilities to form biofilms in vitro revealed that strains that formed thicker biofilms had increased expression of hyphal-specific genes (for example, HWP1) compared with the strains that formed thinner biofilms 79 . Finally, although the core biofilm regulator Bcr1 is not required for hyphal formation per se, it is required for hyphae to adhere to one another 48 , a critical property for maintaining the strength of the biofilm. Consistent with this idea, deletion of either BCR1 or HWP1 resulted in reduced retention of cells within a biofilm 61, 68 . Thus, hyphae in the C. albicans biofilm seem to provide a scaffold for other cells and the matrix, resulting in a resilient structure that is several hundred micrometres thick. The extensive hyphal networks observed in mature C. albicans biofilms are a hallmark that distinguish C. albicans biofilms from those of closely related species such as Candida parapsilosis, which tend to have fewer and shorter hyphae 80 ; this difference may result in the increased strength of C. albicans biofilms relative to those of other species 1 .
Dispersion. The dispersal of C. albicans into the surrounding environment (primarily as round, yeast-form cells) occurs throughout biofilm formation, with greater numbers of cells being dispersed once the biofilm reaches maturity 28, 81 . Dispersed cells can initiate the formation of new biofilms, lead to systemic infections in the bloodstream of the host, or disseminate into host tissues, thus spreading the infection. The transcriptional regulators Ume6, Nrg1 and Pes1 (also known as Nop7) have all been linked to dispersal; overexpression of UME6 reduces dispersal, whereas overexpression of either NRG1 or PES1 increases the number of cells released from the biofilm 28,82 . Set3, a component of a chromatin-modifying complex, is also required for dispersal, probably by being recruited to specific genes by the transcriptional regulator Nrg1 (REFS 81, 83) . In addition, deletion of the molecular chaperone Hsp90 and the cell wall protein Ywp1 reduced dispersal [84] [85] [86] . Moreover, although both nutrient limitation and nutrient excess have been hypothesized to influence dispersion 87 , recent evidence indicates that more cells are dispersed in nutrient-rich medium than in nutrient-poor medium 28, 88 . However, future studies are required to determine how these environmental changes lead to changes in dispersion.
Specific properties of biofilm cells Cells in C. albicans biofilms have several properties that are distinct from those of planktonic cells. A combination of genetic screens, genome-wide transcriptional profiling and proteomics has been used to study C. albicans biofilm development [46] [47] [48] 64, 70, [89] [90] [91] , and these approaches have uncovered major differences between cells of biofilms and those of exponentially growing suspension cultures. For example, RNA-sequencing studies identified ~1,600 genes that were upregulated and ~600 genes that were downregulated in cells in biofilms compared with cells grown in suspension cultures 46 , accounting for approximately 35% of the protein-coding genes in the haploid genome. When gene expression patterns were compared between biofilms and suspension-cultured cells in the stationary phase, additional differences were uncovered. For example, some metabolic pathways that are downregulated in cells during stationary growth (compared with exponentially growing cells) have been reported to be further downregulated in cells of biofilms. However, other pathways that are downregulated in stationary growth (compared with exponential growth) are highly active in biofilm cells 47, 92 . The differences between biofilm and planktonic cells extend beyond their metabolic activities; for example, several secreted proteases are upregulated in biofilm cells but not in planktonic cells, which results in distinct proteolytic cleavage profiles for each growth state 91 . Moreover, differential gene expression profiles have also been noted for specific stages of biofilm formation; for example, ~250 genes were upregulated and ~150 genes were downregulated in cells that had just adhered to a surface compared with the cells that are not adhered in the same medium 47 . Finally, when compared with 'standard' planktonic cells, the yeast-form cells that disperse from mature biofilms seem to be more virulent and to have increased abilities to adhere to surfaces to form new biofilms 28 . In the following section, we discuss two of these differences, increased drug resistance and altered detection by the host immune system. Antifungal drug resistance. C. albicans biofilms are resistant to currently available antifungal drugs, although this resistance is less pronounced for the echino candin class of antifungals 93, 94 . This resistance is due to a combination of factors, including increased expression of drug efflux pumps (even in the absence of drugs), protective features of the extracellular matrix, and the existence of 'persister' cells in the biofilm (see below) (FIG. 3) . Drug resistance is a serious issue for treating biofilm-based infections; in fact, the azole class of drugs, a common initial therapeutic for C. albicans infections, is largely ineffective against biofilms
. Given the limited options, when a device-localized biofilm infection is suspected, removal of the medical device is typically recommended instead of antifungal treatments 95 . C. albicans has two main classes of efflux pumps, the major facilitator (MF) and ATP binding cassette (ABC) transporter superfamilies [96] [97] [98] [99] . Several efflux pumps are upregulated in the presence of antifungal drugs in planktonic cells, and mutations that lead to the constitutive upregulation of efflux pumps such as mutations in the promoters of the genes encoding Cdr1, Cdr2 or Mdr1 (or in transcriptional regulators that control their expression) are frequently associated with increased resistance to antifungal drugs 100 . The upregulation of genes encoding efflux pumps (even in the absence of drugs) seems to be a core part of the biofilm transcriptional programme 46, 47 ; several efflux pumps are upregu lated early during the biofilm developmental process, within 6 h of adherence. Some of these efflux pumps are only transiently upregulated (for example, Nag3 and Nag4) 47 , whereas others (for example, Cdr1, Cdr2 and Mdr1) remain upregulated in mature biofilms 46, 98, 99, [101] [102] [103] . In addition to contributing to the structural features of the biofilm itself, the extracellular matrix is thought to sequester antifungal drugs and provide a physical barrier. Both eDNA and polysaccharides in the matrix have been found to contribute to antifungal resistance; compromising either of these components (for example by treatment with DNase I or β-1,3-glucanase, or by deletion of genes that encode enzymes involved in the synthesis of mannan, β-1,6-glucan or β-1,3-glucan) were shown to increase sensitivity to antifungal drugs 74, [104] [105] [106] . Likewise, the addition of exogenous β-1,3-glucan to medium was found to increase the resistance of planktonic cells to fluconazole 104 . Moreover, the matrix component β-1,3-glucan has also been shown to bind to and sequester the antifungal drug amphotericin B 107 . During C. albicans biofilm development, but not during planktonic growth, persister cells develop stochastically by an unknown mechanism 108 . These persister cells can revert back to metabolically active cells and contribute to the reformation of the biofilm once the antifungal drug has been removed 109 . Indeed, following treatment of a C. albicans biofilm with high doses of amphotericin B, a fraction of cells remained viable at drug concentrations well above those that killed most cells in the biofilm 108, 110, 111 . Based on extrapolations from persister cells in other microbial species, two hypotheses have been advanced: C. albicans persister cells exhibit low metabolic activity, and persister cells are stochastically upregulated for the stress response at the time the drug is added. Consistent with both hypotheses, a recent proteomics study found that the protein levels of many metabolic enzymes (including several enzymes involved . Positive values indicate genes whose expression is upregulated in biofilms and negative values indicate genes whose expression is downregulated in biofilms. ‡ Based on previously published studies of genome-wide chromatin immunoprecipitation followed by DNA microarray (ChIP-chip) data for Bcr1, Brg1, Efg1, Ndt80, Rob1, Tec1 (REF. 46 ) and chromatin immunoprecipitation coupled with quantitative PCR (ChIP-qPCR) data for Flo8, Gal4, Rfx2
Binding by Flo8, Gal4 and Rfx2 has been evaluated only for the control regions of the nine core regulators; all other genes have been evaluated for binding by Bcr1, Brg1, Efg1, Ndt80, Rob1 and Tec1.
Complement system
A group of proteins that, when activated, mediate the innate immune response and inflammatory response to a pathogen.
Mucin
A glycosylated protein that is the major component of mucus.
in ergosterol biosynthesis, which is the target of azole class of drugs) were downregulated in persister cells compared with control cells in a biofilm, while the levels of proteins involved in the stress response and proteins maintaining the integrity of the cell wall were highly upregulated 92 . The fact that a number of genes and metabolic pathways involved in glycolysis, the electron transport chain and the tricarboxylic acid cycle are downregulated in biofilm cells, even below the levels observed in planktonic cells growing in the stationary phase, is also consistent with a link between low rates of metabolism and drug resistance in biofilms 47 . Finally, a recent study found that levels of the alkyl hydroperoxide reductase Ahp1 (a cell wall peroxidase involved in the response to oxidative stress) directly correlated with the fraction of persister cells that survived exposure to amphotericin B 112 , a result consistent with the persister cells expressing higher levels of the gene.
Evasion of host immunity and detection.
A range of host immune cells, including epithelial cells, neutrophils, macro phages and dendritic cells, have key roles in the recognition of and elimination of C. albicans (Supplementary information S1 (box)). C. albicans uses several strategies to evade the host immune response, many of which are linked to biofilms. For example, the hyphal cells in the top layer of mature biofilms 'mask' their β-glucans (a cell wall feature recognized by the immune system), have the ability to penetrate epithelial cell layers during invasive growth, and mediate escape from phagocytic cells by physically piercing the phagocytic cell 113 . The differential expression of genes in cells in biofilms compared with planktonic cells has been linked to immune evasion mechanisms of the former. The activation of the host complement system is blocked by C. albicans Pra1 (an antigenic, zinc-binding cell surface protein) and Gpd2 (a glycerol-3-phosphate dehydrogenase that is found at the cell surface), as well as members of the secreted aspartyl protease (Sap) family 114 ; these proteins are all highly expressed during biofilm formation. Moreover, Msb2, a mucin that functions as a cell wall damage sensor and is also highly expressed in biofilms, protects C. albicans from host-secreted antimicrobial peptides 115, 116 . Although neutrophils may surround biofilms in vivo, they often fail to engulf biofilm cells, possibly because of the protective matrix 117 . In the presence of biofilm cells, neutrophils also fail to trigger a reactive oxygen species response, although the mechanisms for this are unknown 118 . Building on this observation, it has also been shown that the extracellular matrix of C. albicans biofilms helps to block the release of neutrophil extra cellular traps (NETs), thus reducing neutrophilmediated killing 119 . In support of this, decreased production of the extracellular matrix leads to increased NET levels and decreased fungal proliferation 119 . Mature C. albicans biofilms consist of a mixture of distinct cell types (including yeast-form, hyphal and pseudohyphal cells; FIG. 1 ) and distinct microenvironments (for example, hypoxic niches within the depths of the biofilm and aerobic niches near the biofilm surface); this heterogeneity also extends to the transcriptomes and proteomes of individual cells. This broad cellular diversity may be a key aspect that contributes to the resistance of biofilms to antifungal agents and the host immune system because any threat to the biofilm must address multiple targets rather than just a single type of cell. Coupled with the extracellular matrix and the physical architecture of the biofilm itself, given that its large, interconnected nature functions as a barrier to innate immune cells, it is not surprising that the biofilm state is the preferred state of C. albicans in stressful environments, such as in the presence of antifungal drugs or the host immune response.
Polymicrobial biofilms
The human microbiota includes bacteria, archaea and fungi, providing numerous opportunities for physical and chemical interactions between different species and even different kingdoms. Dental caries (oral cavities), periodontitis (gum disease), otitis media (ear infections), diabetic wound infections, chronic pulmonary infections (for example, cystic fibrosis), urinary tract infections and medical device infections are among the many ailments that are caused by polymicrobial biofilm formation 120 (FIG. 4a) .
Polymicrobial infections are observed at an even higher frequency in immunocompromised patients 32, 120, 121 . C. albicans is the fungal pathogen most frequently isolated from mixed bacterial-fungal infections (FIG. 4a) . For example, Staphylococcus aureus and C. albicans are often co-isolated from neonatal polymicrobial bloodstream infections 122 . Biofilms containing C. albicans and Streptococcus mutans or Streptococcus gordonii have been isolated from denture stomatitis and dental carries [123] [124] [125] [126] , whereas C. albicans and Pseudomonas aeruginosa are commonly co-isolated from skin and lung infections 127 . Scanning electron microscopy studies of dual-species biofilms has revealed that cells from species such as Staphylococcus epidermidis, Acinetobacter baumannii, Pseudomonas aeruginosa and various Streptococcus species bind to C. albicans hyphal cells present in a Nature Reviews | Microbiology ) . The extracellular matrix functions as a physical barrier to antifungal drugs. Cells within the biofilm also exhibit increased cell density, increased stress response and decreased metabolic activity, which all contribute to antifungal drug resistance. A minority cell population, called 'persister' cells (shown in orange), can exist in the basal layer of the biofilm. Persister cells are non-dividing cells with decreased metabolic activities, making them highly resistant to antimicrobial drugs and likely to seed new biofilm infections after drug treatment. Efflux pumps export drug molecules from the inside the cell to the environment. Expression of these efflux pumps is highly upregulated in C. albicans biofilms, even in the absence of antifungal drugs, which contributes to the overall drug-resistant nature of biofilms. 
Bacteriocin
A pore-forming peptide produced by some bacterial and archaeal species that is toxic to other microorganisms. biofilm 121, 128 (FIG. 4b) . Other studies have demonstrated that C. albicans adhesion proteins (for example, Als1, Als2 and Als3), hyphal wall proteins (for example, Hwp1) and transcription regulators (for example, Bcr1 and Tec1) play crucial roles in the interactions between C. albicans and bacterial species such as S. epidermidis, S. gordonii and S. aureus [129] [130] [131] ; deletion of these proteins results in fewer bacteria bound to C. albicans as well as weaker adhesion of interacting bacteria. Several of these in vitro findings have also been observed in a murine model of oral candidiasis 132 . Some relationships between C. albicans and bacterial species are synergistic, providing protection to one or both species in the context of dual-species biofilms 133 (FIG. 4c) . For example, when C. albicans and methicillinresistant S. aureus (MRSA) strains were grown together in a biofilm, the presence of C. albicans seemed to protect the MRSA strain from elimination by vancomycin, which is an antibiotic that would normally be effective against MRSA 134, 135 . A recent study linked this protection to the C. albicans extracellular matrix; both increased β-1,3-glucan production and exogenous β-1,3-glucan supplementation increased the survival of MRSA in the presence of vancomycin, and this protective effect was reduced if β-1,3-glucan was disrupted or if its synthesis was blocked 136 . In another study, dual-species biofilms were formed between C. albicans and either Bacteroides fragilis or Clostridium perfringens, which are two anaerobic bacterial species that are present in the human gut. C. albicans biofilms provided a protective hypoxic microenvironment that enabled the growth of these strictly anaerobic bacteria within the biofilm, even though the external environment was aerobic 137 (FIG. 4c) . Moreover, when cultured together under planktonic conditions in the presence of ambient oxygen, these anaerobic bacteria induced C. albicans to form 'mini-biofilms' , which are free-floating cellular aggregates resembling miniature biofilms, that incorporated the bacteria within these structures, enabling B. fragilis and C. perfringens to proliferate under otherwise toxic conditions 137 . Thus, the presence of a C. albicans biofilm enables the proliferation of anaerobic pathogens in otherwise-hostile oxygen-rich environments; moreover, the bacteria seem to induce the formation of these protective structures. However, C. albicans-bacteria interactions are not confined to cooperation; for example, P. aeruginosa has been shown to kill C. albicans cells after attachment to C. albicans hyphae 138 , although the underlying mechanism is not understood in detail.
Interspecies interactions are not limited to direct physical contact; some rely on the secretion and diffusion of signalling molecules and others on local environmental changes (for example, alterations in pH, oxygen or carbon dioxide levels) to influence the behaviour of one species towards the other 32,133 (FIG. 4d,e) . For example, studies on the vaginal microbiota have revealed that Lactobacillus species lower the local pH (by releasing lactic acid), which results in the inhibition of C. albicans initial adherence to the vaginal mucosal surface 139 (FIG. 4e) .
Extensive research on the crosstalk between P. aeruginosa and C. albicans has revealed that each species secretes a similarly structured quorum sensing molecule that can be detected by the other species. For example, the 12-carbon acyl homoserine lactone, which is secreted by P. aeruginosa, inhibits C. albicans hyphal growth 140, 141 ( FIG. 4d) . Similarly, Enterococcus faecalis secretes the bacteriocin EntV, which inhibits C. albicans hyphal and biofilm formation and disrupts mature C. albicans biofilms 142 . Finally, the LuxS quorum sensing system in S. gordonii is needed for the increase in biomass observed when S. gordonii and C. albicans form a dual-species biofilm 125 . The S. gordonii luxS mutant strain is less capable of inducing C. albicans hyphal growth than the wildtype S. gordonii strain and causes an overall reduction in biomass of the dual-species biofilm formed. This reduction in biomass is not due to a general biofilm defect in the luxS strain; the single-species biofilms formed by the luxS and wild-type strains are similar in biomass 125 . Other fascinating, but less explored, interactions include the sharing of nutrients and the exchange of electrons between microbial species during biofilm formation 143, 144 ( FIG. 4f) . The latter interaction is particularly intriguing in the context of polymicrobial biofilms, as it enables microorganisms of different species to gain energy from a series of reactions that a single species might lack. This strategy has been well documented for methane-producing and anaerobic polymicrobial biofilms found in the environment 145 . To our knowledge, the positive feedback loop between phenazine production in P. aeruginosa and ethanol production in C. albicans is the only instance in which such a strategy has been documented for polymicrobial biofilms that are relevant to human health 146, 147 . Exposure to sub-toxic concentrations of phenazines results in the increased production of fermentation products, such as ethanol, by C. albicans. In response to the resulting increased ethanol levels, P. aeruginosa increases production of phenazine and promotes its own biofilm formation. This interaction has been shown to increase
Box 2 | Antifungal drugs
Four major classes of antifungal drugs are in common use to treat invasive fungal infections 25, 100 . The oldest class of antifungal drugs is the polyenes (for example, amphotericin B), which are fungicidal against Candida albicans. Polyenes interact with ergosterol in the fungal cell membrane, forming pores that destabilize the membrane and induce lethal leakage of the cytoplasm. Azoles (for example, fluconazole and voriconazole) inhibit a demethylase enzyme (Erg11 in C. albicans) in the ergosterol biosynthesis pathway, which results in the depletion of ergosterol. Azoles also lead to the accumulation of toxic methylated sterol intermediates. Azoles, the most commonly used class of antifungals, have a fungistatic effect on C. albicans. Antifungals of the newest class, the echinocandins (for example, caspofungin), have a fungicidal effect on C. albicans. They inhibit the synthesis of β-1,3-glucan, which is important for cell wall crosslinking; this inhibition affects cell wall integrity and ultimately causes osmotic lysis of the cell. The final, less commonly used class of antifungal drugs is made up of the pyrimidine or nucleoside analogues, of which flucytosine (5-FC) is a common example. 5-FC is converted by the fungal cell into compounds that mimic nucleotides that become incorporated into DNA or RNA, interfering with fungal DNA replication and protein synthesis.
Common mechanisms of azole antifungal drug resistance include upregulation of (or point mutations within) genes whose products are directly inhibited by antifungal drugs (for example, Erg11), compensatory mutations or regulatory changes elsewhere in targeted pathways (for example, Erg3 in the ergosterol biosynthesis pathway), and upregulation of efflux pumps that export drugs from the cell (for example, Cdr1 and Mdr1) 100 . P. aeruginosa biofilm formation on bronchial epithelial cells and could, in principle, lead to increased virulence for both species in the host 146, 147 .
Other interactions between C. albicans and bacterial partners can also affect virulence during an infection 133 . For example, when C. albicans and specific oral Streptococcus species, such as Streptococcus oralis, S. sanguinis, or S. gordonii, were placed in a flow-cell-based oral-cavity infection model, the two species demonstrated a cooperative interaction that increased tissue invasion and colonization compared with monotypic infections 148 . Similar synergies in virulence have been observed for other C. albicans-bacterial dual-species interactions; for example, higher host mortality was observed when S. aureus and C. albicans were introduced together at sub-lethal doses in a mouse peritonitis infection model compared with infections with either species alone 123 . The broad range of synergies that have been observed between two or more microorganisms has implications for the treatment of infections. For example, treatment of a polymicrobial biofilm in the catheter of a patient is particularly difficult, often leading to the removal of the device instead. Further studies are needed to understand the complexity of polymicrobial biofilm infections and interspecies interactions to guide the development of new therapeutic strategies.
Conclusion
The medical impact of C. albicans on its human host depends on its ability to form biofilms, which are densely packed communities of cells that adhere to a range of biotic and abiotic surfaces. The specific characteristics of biofilms, especially their resistance to existing antifungal drugs, their ability to evade components of the host immune response, their stability to mechanical forces, and their ability to seed new infections, make them an important clinical problem. Work to date has identified numerous potential starting points for more focused examinations of specific stages of the biofilm life cycle. More targeted studies of the initial adhesion of C. albicans cells to solid surfaces, the subsequent development of mature biofilms, the formation of the extracellular matrix, the formation of persister cells, and the mechanism of dispersion have identified numerous gene products required for each of these steps 28, 47, 70, 92 , although the function of many of them is unknown. Recent work on dual-species biofilms and the protection that they can provide for each species has revealed fascinating ways in which distantly related microorganisms work closely together.
Despite these recent advances, we still lack a clear, comprehensive understanding of the processes involved in the development of a biofilm, even in the simplest case of a pure C. albicans biofilm forming under controlled, in vitro conditions. For example, we do not know how environmental signals and proteins other than transcriptional regulators (such as kinases and cell wall proteins) feed into the biofilm regulatory circuitry. Likewise, more information is needed about the temporal regulation of biofilms, particularly how cells 'decide' to advance to later stages of the life cycle. We also do not understand how the different cell types in a biofilm are produced and organized in a biofilm. Another intriguing question concerns whether biofilm cells have a 'cell memory' and whether it persists in cells that are dispersed from biofilms. Finally, and perhaps most importantly, the roles of the great majority of genes upregulated during biofilm formation are simply not known.
Although not strictly a developmental process, biofilm formation could be profitably studied in the future using many of the tools used in developmental biology, such as lineage tracers and distinct fluorescent makers for each cell type. Widespread use of recently developed assays to track biofilm development in live rodent hosts in real time will undoubtedly challenge and change much of our current understanding of biofilms 149, 150 . Finally, the study of mixed C. albicans-bacterial biofilms, although only beginning, has already revealed unanticipated synergies that further complicate the treatment of biofilms in the clinic. In the end, it is hoped that these studies will lead to new therapies to prevent, disrupt and otherwise render harmless the peculiar ability of C. albicans to form biofilms on almost any surface in the human body.
